[Radical prostatectomy in patients with Gleason 6 (ISUP 1) prostate cancer: 10-year follow-up]

Prog Urol. 2022 Feb;32(2):108-114. doi: 10.1016/j.purol.2021.10.008. Epub 2021 Dec 14.
[Article in French]

Abstract

Objective: To evaluate extraprostatic extension and 10 years cancer specific survival in a population of patients with Gleason 6 (ISUP 1) prostate cancer (PCa) treated by radical prostatectomy (RP) in two French third referral centers.

Materials and methods: The data were extracted from 2 university hospital databases according to the following criteria: PCa classified ISUP 1 following both biopsy (PB) and surgery (RP) between 1998 and 2008. Pathology slides of patients having presented an extraprostatic extension and/or a recurrence were reviewed by a uropathologist.

Results: Among the 534 patients who met the inclusion criteria, 66 (12.2%) had a pT3 stage. One patient out of 198 who received lymph node dissection had a positive node. Median follow-up was 10.3 years. Only one patient presented with metastatic progression. No cancer specific death was observed. An independent pathologist reviewed the slides of 58 out of the 70 patients who presented pT3 disease and/or a recurrence (in 12 cases, pathological material was not available). After review, all pT3b stages and 12 pT3a (out of 14) were upgraded to ISUP2 or higher. Similarly, the patient with a positive node and the patient who progressed towards a metastatic disease were both upgraded to ISUP 3.

Conclusion: No pT3b or pN+stage was associated with ISUP 1 PCa in our study. With a median follow-up of more than 10 years, biological progression was the only type of progression observed.

Keywords: Cancer de prostate; Neoplasm grading; Prostate cancer; Prostatectomie; Prostatectomy; Score de Gleason.

MeSH terms

  • Follow-Up Studies
  • Humans
  • Male
  • Neoplasm Grading
  • Neoplasm Staging
  • Prostate / pathology
  • Prostate / surgery
  • Prostate-Specific Antigen
  • Prostatectomy*
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / surgery

Substances

  • Prostate-Specific Antigen